1. "Biostatistics Service"
  2. "Nursing"
  3. "Survivorship Research"
  4. "2017"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (4)
Groups
  1. Biostatistics Service (20)
  2. Epidemiology and Biostatistics (20)
  3. Nursing (20)
  4. Survivorship Research (20)
  5. Department of Medicine (19)
  6. Center for Hematologic Malignancies (17)

More Groups

People
  1. Miguel-Angel Perales (11)
  2. Sean Devlin (10)
  3. Guenther Koehne (9)
  4. Gunjan Shah (9)
  5. Sergio Giralt (9)
  6. Molly Maloy (7)

More People

Years
  1. 2017 (20)
Publications
  1. Biology of Blood and Marrow Transplantation (7)
  2. Blood (3)
  3. Hematological Oncology (3)
  4. Journal of Clinical Oncology (2)
  5. Bone Marrow Transplantation (1)
  6. Cancer Research (1)

More Publications

Publishers
  1. Elsevier Inc. (8)
  2. American Society of Hematology (3)
  3. Wiley Blackwell (3)
  4. American Society of Clinical Oncology (2)
  5. American Association for Cancer Research (1)
  6. American College of Chest Physicians (1)

More Publishers

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Toxicities and outcomes in the first year after ex-vivo CD34+ selected allogeneic hematopoietic cell transplantation in adults with hematologic malignancies
    Meeting Abstract

    Kosuri, S.; Herrera, D. A. A.; Scordo, M.; Shah, G. L.; Devlin, S. M.; Maloy, M.; Nieves, J.; Cho, C.; Borrill, T.; Carlow, D.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Safety and efficacy of re-immunization with inactivated vaccines in multiple myeloma patients on lenalidomide maintenance following autologous hematopoietic stem cell transplantation (auto HCT)
    Meeting Abstract

    Palazzo, M.; Shah, G. L.; Copelan, O.; Seier, K.; Devlin, S. M.; Hassoun, H.; Korde, N. S.; Lendvai, N.; Lesokhin, A. M.; Mailankody, S.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Post-transplant toxicities and outcomes in long-term survivors of ex-vivo CD34+ selected allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Scordo, M.; Shah, G. L.; Kosuri, S.; Herrera, D. A.; Cho, C.; Devlin, S. M.; Maloy, M.; Nieves, J.; Borrill, T.; Carlow, D.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Immune-mediated hemolytic anemia (IMHA) and immune thrombocytopenia (ITP) after ex-vivo CD34+ selected allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Scordo, M.; Shah, G. L.; Kosuri, S.; Adrianzen Herrera, D. A.; Hsu, M.; Devlin, S. M.; Maloy, M.; Nieves, J.; Borrill, T.; Avecilla, S. T.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Comparable survival with organ toxicity predicting for overall survival (OS) and non-relapse mortality (NRM) in older adult patients after CD34+ selected allogeneic hematopoietic stem cell transplantation (Allo-HCT)
    Meeting Abstract

    Shah, G. L.; Scordo, M.; Kosuri, S.; Adrianzen Herrera, D. A.; Cho, C.; Maloy, M.; Nieves, J.; Devlin, S. M.; Borrill, T.; Carlow, D.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC)
    Meeting Abstract

    Lowery, M. A.; O'Reilly, E. M.; Harding, J. J.; Yu, K. H.; Cercek, A.; Hollywood, E.; Salehi, E.; Margona, E.; Bradley, M.; Witter, T.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mailankody, S.; Smith, E. L.; Lendvai, N.; Hassoun, H.; Lesokhin, A.; Hultcrantz, M.; Chung, D. J.; Shah, G. L.; Koehne, G.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Vaccines are safe and effective after T-cell depleted CD34-selected allogeneic hematopoietic stem cell transplantation (Allo HCT)
    Meeting Abstract

    Malard, F.; Shah, G. L.; Seier, K.; Cho, C.; Devlin, S. M.; Maloy, M.; Borrill, T.; Palazzo, M.; van den Brink, M.; Perales, M. A.
    Bone Marrow Transplantation (2017)

    Fulltext@MSK | Save